Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 May 7;29(1):43.
doi: 10.1186/1756-9966-29-43.

The expression and significance of IDH1 and p53 in osteosarcoma

Affiliations

The expression and significance of IDH1 and p53 in osteosarcoma

Xiang Hu et al. J Exp Clin Cancer Res. .

Abstract

Background: To detect the expression of isocitrate dehydrogenase 1 (IDH1) and transformation-related protein 53 (p53) in osteosarcoma and analyze the correlation between them and the clinico-pathological features.

Methods: The expressions of IDH1 and p53 were detected in human osteosarcoma cell lines (MG-63 and U2OS) by immunocytochemistry, Real-time PCR and Western Blotting. The expressions of IDH1 and p53 in formalin-fixed paraffin-embedded tissue sections from 44 osteosarcoma patients were determined by immunohistochemistry, and the correlation between them and clinicopagthological features were analyzed. None of these patients received chemotherapy prior to surgery.

Results: IDH1 is detected in osteosarcoma cell lines and biopsies. IDH1 expresses higher in U2OS cells with wild type p53 than in MG-63 cells with mutation p53. IDH1 correlates with histological Rosen grade and metastasis negatively. P53 correlates with histological Rosen grade, metastasis and overall survival in clinical osteosarcoma biopsies. Osteosarcoma patients with High IDH1 expression have a very high p53 expression.

Conclusion: IDH1 may correlate with p53 and be a candidate biomarker for osteosarcoma correlate with histological Rosen grade and metastasis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The immunocytochemistry of IDH1 in MG63 and U2OS. IDH1 is specifically detected in the cytoplasm of both osteosarcoma cell lines MG63 and U2OS.(A) Expression of IDH1 in U2OS, × 200; (B) Expression of IDH1 in MG63,× 200; (C) Expression of IDH1 in U2OS,× 400; (D) Expression of IDH1 in MG63,× 400.
Figure 2
Figure 2
The mRNA levels of IDH1 in MG63 and U2OS (on fold). The mRNA levels of IDH1 is higher in U2OS than in MG63(P < 0.01).
Figure 3
Figure 3
The protein expression levels of IDH1 and p53 in U2OS and MG63. MG63 demonstrates no detectable p53 while U2OS cells demonstrates a high expressed p53. IDH1 expresses higher in U2OS than in MG63 at the protein level(P < 0.01).
Figure 4
Figure 4
The expression of IDH1 and p53 in low histological Rosen grade biopsy. IDH1 expresses at high level accompanying with high expressed p53 in Low histological Rosen grade biopsy.(A) Expression of IDH1 in low histological Rosen grade biopsy, × 100;(B) Expression of p53 in low histological Rosen grade biopsy, × 100; (C) Expression of IDH1 in low histological Rosen grade biopsy, × 200;(D) Expression of p53 in low histological Rosen grade biopsy, × 200.
Figure 5
Figure 5
The expression of IDH1 and p53 in high histological Rosen grade biopsy. IDH1 expresses at low level accompanying with low expressed p53 in high histological Rosen grade biopsy.(A) Expression of IDH1 in high histological Rosen grade biopsy, × 100;(B) Expression of p53 in high histological Rosen grade biopsy, × 100; (C) Expression of IDH1 in high histological Rosen grade biopsy, × 200;(D) Expression of p53 in high histological Rosen grade biopsy, × 200.
Figure 6
Figure 6
The immunostaining percentages of IDH1 and p53 in low Rosen grade vs. high Rosen grade. IDH1 expresses higher in Low histological Rosen grade compare with high histological Rosen grade at the level of the immunostaining percentages (P < 0.01), so does p53 (P < 0.01).
Figure 7
Figure 7
The immunostaining scores of IDH1 and p53 in low Rosen grade vs. high Rosen grade. IDH1 expresses higher in Low histological Rosen grade compare with high histological Rosen grade at the level of the immunostaining scores (P < 0.05), so does p53 (P < 0.01).
Figure 8
Figure 8
The relationship between IDH1 and survival. The IDH1 high expression group represents the osteosarcoma patients with >50% IDH1 positive staining. Patients with ≤ 50% IDH1 positive staining are recorded as low-expression group. The survival time in the χ -axis was given as years. There is no significant correlation between IDH1 expression and overall survival (P = 0.342).
Figure 9
Figure 9
The relationship between p53 and survival. The p53 high expression group represents the osteosarcoma patients with >50% p53 positive staining. Patients with ≤ 50% p53 positive staining are recorded as low-expression group. The survival time in the χ-axis was given as years. High-expression p53 patients have better survival than low-expression p53 patients do (P = 0.019).

Similar articles

Cited by

References

    1. Kager L, Zoubek A, Pötschger U, Kastner U, Flege S, Kempf-Bielack B, Branscheid D, Kotz R, Salzer-Kuntschik M, Winkelmann W, Jundt G, Kabisch H, Reichardt P, Jürgens H, Gadner H, Bielack SS. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2003;21:2011–2018. doi: 10.1200/JCO.2003.08.132. - DOI - PubMed
    1. Ferguson WS, Goorin AM. Current treatment of osteosarcoma. Cancer Invest. 2001;19:292–315. doi: 10.1081/CNV-100102557. - DOI - PubMed
    1. Overholtzer M, Rao PH, Favis R, Lu XY, Elowitz MB, Barany F, Ladanyi M, Gorlick R, Levine AJ. The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability. Proceedings of the National Academy of Sciences of the United States of America. 2003;100:11547–11552. doi: 10.1073/pnas.1934852100. - DOI - PMC - PubMed
    1. Zheng Shui-er, Yso Yang, Dong Yang, Lin Feng, Zhao Hui, Shen Zan, Sun Yuan-jue, Tang Li-na. Down-regulation of ribosomal protein L7A in human osteosarcoma. J Cancer Res Clin Oncol. 2009;135:1025–1031. doi: 10.1007/s00432-008-0538-4. - DOI - PubMed
    1. Saleh HA, Jin B, Barnwell J, Alzohaili O. Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules. Diagn Pathol. 2010;26:5–9. - PMC - PubMed

Publication types